Non-Hodgkin lymphoma mortality statistics

Deaths

Deaths from non-Hodgkin lymphoma, 2014, UK

 

Proportion of all deaths

Percentage non-Hodgkin lymphoma is of total cancer deaths, 2014, UK

 

Age

Peak rate of non-Hodgkin lymphoma deaths, 2012-2014, UK

 

Trend over time

Non-Hodgkin lymphoma mortality rates have increased by 83% since the early 1970s, UK

 

Non-Hodgkin lymphoma (NHL) is the 10th most common cause of cancer death in the UK (2014), accounting for 3% of all cancer deaths.[1-3] In males, it is the 12th most common cause of cancer death in the UK (3% of all male cancer deaths), whilst it is the eighth most common cause of cancer death in females in the UK (3% of all female cancer deaths).[1-3]

In 2014, there were 4,801 NHL deaths in the UK: 2,618 (55%) in males and 2,183 (45%) in females, giving a male:female ratio of around 12:10.[1-3] The crude mortality rate Open a glossary item shows that there are 8 NHL deaths for every 100,000 males in the UK, and 7 for every 100,000 females.

The European age-standardised mortality rates Open a glossary item (AS rates) is significantly lower in Scotland compared with England for males only. There are no significant differences between the other constituent countries of the UK for either sex.[1-3]

Non-Hodgkin Lymphoma (C82-C86), Number of Deaths, Crude and European Age-Standardised (AS) Mortality Rates per 100,000 Population, UK, 2014

England Wales Scotland Northern Ireland UK
Male Deaths 2,243 129 179 67 2,618
Crude Rate 8.4 8.5 6.9 7.4 8.2
AS Rate 10.4 9.3 8.3 10.8 10.2
AS Rate - 95% LCL 10.0 7.7 7.1 8.2 9.8
AS Rate - 95% UCL 10.9 10.9 9.5 13.3 10.6
Female Deaths 1,812 110 196 65 2,183
Crude Rate 6.6 7.0 7.1 6.9 6.7
AS Rate 6.5 6.4 7.0 7.7 6.6
AS Rate - 95% LCL 6.2 5.2 6.0 5.8 6.3
AS Rate - 95% UCL 6.8 7.6 7.9 9.5 6.9
Persons Deaths 4,055 239 375 132 4,801
Crude Rate 7.5 7.7 7.0 7.2 7.4
AS Rate 8.2 7.8 7.6 9.0 8.2
AS Rate - 95% LCL 8.0 6.8 6.8 7.5 7.9
AS Rate - 95% UCL 8.5 8.7 8.4 10.5 8.4

95% LCL and 95% UCL are the 95% lower and upper confidence limits Open a glossary item around the AS Rate Open a glossary item

NHL mortality rates across the UK show some variation by health boundaries for both males and females; however, as with variation in incidence, this is probably associated with differences in registration practices.[4-6]

References

  1. Data were provided by the Office for National Statistics on request, November 2015. Similar data can be found here: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsregistrationsummarytables/previousReleases.
  2. Data are provided by Information Services Division (ISD) Scotland on request, November 2015. Similar data can be found here: http://www.nrscotland.gov.uk/statistics-and-data/statistics/statistics-by-theme/vital-events/vital-events-reference-tables.
  3. Data were provided by the Northern Ireland Statistics and Research Agency on request, November 2015. Similar data can be found here:http://www.nisra.gov.uk/demography/default.asp2.htm.
  4. National Cancer Intelligence Network (NCIN). Cancer Incidence and Mortality by Cancer Network, UK, 2005. London: NCIN; 2008.
  5. National Cancer Intelligence Network (NCIN). Cancer e-Atlas. Accessed at:http://www.ncin.org.uk/cancer_information_tools/eatlas/default.aspx.
  6. Haematological Malignancy Research Network. Haematological malignancies & cancer registration in England (2004-2008). Quality appraisal comparing data from the National Cancer Data Repository (NCDR) with the population-based Haematological Malignancy Research Network (HMRN). Final Report. London: Leukaemia & Lymphoma Research; 2012.
Last reviewed:

NHL mortality is strongly related to age, with the highest mortality rates being in older males and females. In the UK in 2012-2014, on average each year almost 6 in 10 (56%) deaths were in people aged 75 and over.[1-3]

Age-specific mortality rates rise gradually from around age 45-49, and more sharply from around age 55-59 with the highest rates in the 90+ age group. Mortality rates are significantly higher for males than for females in those aged 45-49 and over and this gap is widest at the ages of 45-49, when the male:female ratio of age-specific rates (to account for the different proportions of males to females in each age group) is around 22:10.[1-3]

Non-Hodgkin Lymphoma (C82-C85), Average Number of Deaths per Year and Age-Specific Mortality Rates, UK, 2012-2014

For most cancer types, mortality by age largely reflects incidence and survival by age, e.g. typically, higher incidence and lower survival in older people results in higher mortality in older people.

References

  1. Data were provided by the Office for National Statistics on request, November 2015. Similar data can be found here: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsregistrationsummarytables/previousReleases.
  2. Data were provided by the Information Services Division (ISD) Scotland on request, November 2015. Similar data can be found here: http://www.nrscotland.gov.uk/statistics-and-data/statistics/statistics-by-theme/vital-events/vital-events-reference-tables.
  3. Data were provided by the Northern Ireland Statistics and Research Agency on request, November 2015.Similar data can be found here: http://www.nisra.gov.uk/demography/default.asp2.htm.
Last reviewed:

Non-Hodgkin Lymphoma (NHL) mortality rates have increased by 83% in the UK since the early 1970s.[1-3] This includes a larger overall increase for males than females. For both sexes there has been an increase followed by a decrease during this time.

For males, European Age-Standardised Open a glossary item (AS) mortality rates increased by 106% between 1971-1973 and 1995-1997 and then decreased by 9% between 1995-1997 and 2012-2014. For females, rates increased by 109% in between 1971-1973 and 1999-2001 and then decreased by 16% between 1999-2001 and 2012-2014.

Over the last decade in the UK (between 2003-2005 and 2012-2014), NHL AS mortality rates have decreased by 8% for males and females combined, with a similar decrease in males (6%) and females (10%).[1-3]

Non-Hodgkin lymphoma (C82-C85), European Age-Standardised Mortality Rates, UK, 1971-2014

For most cancer types, mortality trends largely reflect incidence and survival trends, e.g. increased incidence without sufficient survival improvement results in increased mortality.

NHL mortality rates have increased overall for people aged 60-69 and over in the UK since the early 1970’s, but have decreased for people aged 50-59 and under.[1-3] The largest increase has been in people aged 80+, with rates increasing by 313% between 1971-1973 and 2012-2014. The largest decrease has been in people aged 0-24, with rates decreasing by 77% between 1971-1973 and 2012-2014.

Non-Hodgkin Lymphoma (C82-C85), European Age-Standardised Mortality Rates, by Age, Persons, UK, 1971-2014

References

  1. Data were provided by the Office for National Statistics on request, November 2015. Similar data can be found here: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsregistrationsummarytables/previousReleases.
  2. Data were provided by the Information Services Division (ISD) Scotland on request, November 2015. Similar data can be found here: http://www.nrscotland.gov.uk/statistics-and-data/statistics/statistics-by-theme/vital-events/vital-events-reference-tables.
  3. Data were provided by the Northern Ireland Statistics and Research Agency on request, November 2015. Similar data can be found here: http://www.nisra.gov.uk/demography/default.asp2.htm.
Last reviewed:

Non-Hodgkin lymphoma (NHL) mortality rates are projected to fall by 20% in the UK between 2014 and 2035, to 8 deaths per 100,000 people by 2035.[1] This includes a larger decrease for males than for females.

For males, non-Hodgkin lymphoma European age-standardised (AS) Open a glossary item mortality rates in the UK are projected to fall by 22% between 2014 and 2035, to 9 deaths per 100,000 by 2035.[1] For females, rates are projected to fall by 20% between 2014 and 2035, to 6 deaths per 100,000 by 2035.[1]

Non-Hodgkin lymphoma (C82-C85), Observed and Projected Age-Standardised Mortality Rates, by Sex, UK, 1979-2035

 

It is projected that 6,129 deaths from non-Hodgkin lymphoma (3,435 in males, 2,694 in females) will occur in the UK in 2035.

References

  1. Smittenaar CR, Petersen KA, Stewart K, Moitt N. Cancer Incidence and Mortality Projections in the UK Until 2035. Brit J Cancer 2016.

About this data

Data is for: UK, 1979-2014 (observed), 2015-2035 (projected), ICD-10 C82-C85

Projections are based on observed incidence and mortality rates and therefore implicitly include changes in cancer risk factors, diagnosis and treatment. It is not possible to assess the statistical significance of changes between 2014 (observed) and 2035 (projected) figures. Confidence intervals are not calculated for the projected figures. Projections are by their nature uncertain because unexpected events in future could change the trend. It is not sensible to calculate a boundary of uncertainty around these already uncertain point estimates. Changes are described as 'increase' or 'decrease' if there is any difference between the point estimates.

More on projections methodology

Last reviewed:

There is evidence for an association between non-Hodgkin lymphoma mortality and deprivation for females in England, but there is no evidence for an association for males.[1] England-wide data for 2007-2011 show European age-standardised Open a glossary item mortality rates are 24% higher for females living in the most deprived areas compared with the least deprived, but for males the rates are similar for those living in the least and most deprived areas.[1]

Non-Hodgkin Lymphoma (C82-C85), European Age-Standardised Mortality Rates by Deprivation Quintile, England, 2007-2011

The estimated deprivation gradient in non-Hodgkin lymphoma mortality for males and females living in the most and least deprived areas in England has not changed in the period 2002-2011.[1] It has been estimated that there would have been around 130 fewer cancer deaths each year in England during 2007-2011 if all people experienced the same mortality rates as the least deprived.[1]

References

  1. Cancer Research UK and National Cancer Intelligence Network. Cancer by deprivation in England: Incidence, 1996-2010, Mortality, 1997-2011. London: NCIN; 2014.

About this data

Data is for: UK, 2007-2011, ICD-10 C82-C85

Deprivation gradient statistics were calculated using mortality data for 2007-2011. The deprivation quintiles were calculated using the Income domain scores from the Index of Multiple Deprivation (IMD) from the following years: 2004, 2007 and 2010. Full details on the data and methodology can be found in the Cancer by Deprivation in England NCIN report.

Last reviewed:

NHL (C82-85 & C96) is the 14th most common cause of cancer death in Europe, with around 37,900 deaths from NHL in 2012 (2% of the total). In Europe (2012), the highest World age-standardised Open a glossary item mortality rates for NHL are in Malta for men and Croatia for women; the lowest rates are in Albania for both men and women. UK NHL mortality rates are estimated to be the 6th highest in males in Europe, and 8th highest in females.[1] These data are broadly in line with Europe-specific data available elsewhere.[2]

NHL (C82-C85 & C96) is the 11th most common cause of cancer death worldwide, with more than 199,000 deaths from NHL in 2012 (2% of the total). NHL mortality rates are highest in Melanesia and lowest in South Central Asia, but this partly reflects varying data quality worldwide.[1]

References

  1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from:http://globocan.iarc.fr, accessed December 2013.
  2. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al.Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. European Journal of Cancer (2013) 49, 1374-1403.

About this data

Data is for: Europe and worldwide, 2012, ICD-10 C82-85 & C96

Last reviewed:

Cancer stats explained

See information and explanations on terminology used for statistics and reporting of cancer, and the methods used to calculate some of our statistics.

Citation

You are welcome to reuse this Cancer Research UK content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:

Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
Graphics (when reused unaltered): Credit: Cancer Research UK.
Graphics (when recreated with differences): Based on a graphic created by Cancer Research UK.

When Cancer Research UK material is used for commercial reasons, we encourage a donation to our life-saving research.
Send a cheque payable to Cancer Research UK to: Cancer Research UK, Angel Building, 407 St John Street, London, EC1V 4AD or

Donate online

Acknowledgements

We are grateful to the many organisations across the UK which collect, analyse, and share the data which we use, and to the patients and public who consent for their data to be used. Find out more about the sources which are essential for our statistics.

Rate this page:

Currently rated: 1.6 out of 5 based on 7 votes
Thank you!
We've recently made some changes to the site, tell us what you think

Share this page